The latest just out from Dr. Lenz on upcoming trials at USC

lisa42 Member Posts: 3,625 Member
edited March 2014 in Colorectal Cancer #1
Hello Everyone- I just copied and pasted what I received on my C3 e-newsletter from "The Desk of Dr. Lenz" at USC in Los Angeles. The main trial he is referring to is one that supposedly targets the cancer stem cells. It will be a phase I trial and looks like it should start about the beg. of November. He discusses other trials also.
When I copied and printed, it didn't show up here looking like it did on the newsletter. If you want to see or read more about what Dr. Lenz has brewing, check it out for yourself online under C3. Check it out at:


C3 Site Update: Update on the PRI724 Trial and Other Trials (plus 1 more)

Update on the PRI724 Trial and Other Trials
Posted: 05 Oct 2010 12:50 PM PDT
Written by Heinz-Josef Lenz, MD.
Because of the overwhelming response through this website and online, I wanted to clarify a little bit more about this trial and other trials available for patients with advanced colorectal cancer who have received all standard of care regimens including FOLFOX, FOLFIRI, Avastin and Erbitux (if they were wild-type KRAS).
Of course we will have PRI724. The reason we are so excited because it is the first in class to inhibit a pathway so essential for colon cancer stem cells.
The IND is filed at the FDA, which means we need to wait 30 days for the FDA to respond. If they have concerns, we need to answer them. When they agree, we will go ahead to get institutional review board (IRB) approval. We already have scientific approval from the Cancer Center Scientific Review. Once we have IRB approval we are ready to go.
In the first phase any solid tumor is eligible. However, phase I trials are heavily regulated, so patients need to meet eligibility criteria, which means almost normal function of renal, liver, blood etc. They have to be in reasonable shape (able to do their daily activities). We anticipate that this trial may open at the beginning of November.
This is a phase I trial, which means we are dose escalating to find out if there are any side effects. We don’t expect any. In fact we are worried that there will be none, which will make it difficult for us to decide what dose to use to move forward.
We have decided to measure concentrations of the drug in the blood stream and changes in the tumor cells to determine when the drug is effective, and then expand the dose to colon and pancreas cancer.
In addition, over the last year a lot of novel therapies have been developed and we have two trials open for patients with mutant KRAS, one for patients who received FOLFOX/Avastin who never had irinotecan, have mutant KRAS, and whose tumors continue to grow. For patients who had all therapies we have another trial.
We also have trials with novel compounds which focus on the VEGFR, but not VEGF like Avastin does. VEGFR is the receptor to which VEGF binds and may work when anti-VEGF does not work. This is a phase III randomized trial using an antibody against VEGFR. The control arm is no treatment.
We have openied a novel trial using lapatinib and LBH and LBH with 5-FU. These novel drugs attack specific alteration in the colon cancer cells. Both combinations were tested in vitro and in animals showing promising data, so we wrote them up for clinical trial.
We have a EPO906 trial which has shown to shrink tumors in patients who had all standard treatments and where those treatments stopped working.
We have phase I trials with inhibitors of Hedgehog, NOTCH, MEK, and others, which are novel smart drugs effecting specific genetic switches turned on in colon cancer. Also there are other trials which also make a lot of sense depending on the molecular make up of your tumor.
I hope this clarifies some of the questions that readers had.
From the Editor
You can find a complete list of gastrointestinal cancer clinical trials currently available at the University of Southern California Norris Cancer Center online. Look for Dr. Lenz’s name as Principal Investigator and for colorectal somewhere in the name of the trial.
Some trials may also be available closer to where you live. Others are limited to USC Norris.
The Clinical Investigation Support Office at (323) 865-0451 at USC Norris can give you more information and answer your questions. Here are answers to some Frequently Asked Questions about clinical trials at USC Norris.
Call the Colorectal Cancer Coalition Answer Line for more help with understanding these trials or finding other clinical trials to meet your needs. 877-4CRC-111 (877-427-2111).


  • HeartofSoul
    HeartofSoul Member Posts: 729 Member
    thank you for the article on
    thank you for the article on Dr Lenz. I live 35 min southwest of USC and grad there in 1979. appreciate the aritcle
  • ritaclough
    ritaclough Member Posts: 44
    Thanks for posting
    Wow a lot in the works. How refreshing to see. Thanks for the update~! I'm going to book mark that site.
  • traci43
    traci43 Member Posts: 773 Member
    video re: clinical trial
    Thanks Lisa, I just came on to post this:

    Dr. Lenz sent me this link to a video about the clinical trial:
  • lisa42
    lisa42 Member Posts: 3,625 Member
    traci43 said:

    video re: clinical trial
    Thanks Lisa, I just came on to post this:

    Dr. Lenz sent me this link to a video about the clinical trial:

    Thanks for the video link Traci! I watched it and it's very exciting & fun to see how excited Dr. Lenz is about this upcoming trial targeting cancer stem cells- supposedly the drug shows no side effects- sounds too good to be true, but maybe it will prove to be amazing!
  • AnneCan
    AnneCan Member Posts: 3,673 Member
    Thank you, Lisa!
    You are passing on hope + information from Dr. Lenz, thanks so much!
  • Nana b
    Nana b Member Posts: 3,030 Member
    AnneCan said:

    Thank you, Lisa!
    You are passing on hope + information from Dr. Lenz, thanks so much!

    Thank you Lisa!
    Let's keep

    Thank you Lisa!

    Let's keep our fingers and toes crossed, if we can even move them! Hugs!